Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Labs and Celera Genomics Link on Cancer Therapeutics Development

NEW YORK, July 7 (GenomeWeb News) - Abbott Laboratories and Celera Genomics Group today announced a partnership to develop therapeutic antibodies and small-molecule drugs against over-expressed cell-surface proteins associated with cancer.


Celera will contribute a subset of the cell-surface antigens it has identified and validated in its ongoing proteomic studies in a number of solid tumors, the company said. Abbott will screen the antigens to identify those with potential for subsequent preclinical development.


In the collaboration, the two companies may elect to jointly fund clinical development and commercialization of any therapeutic products and share the financial returns resulting from this, he companies said. Abbott will be responsible for commercialization of jointly-funded collaboration products.


If either company opts to not jointly clinical development of a resulting product, the terms of the agreement will revert to a milestone and royalty structure. Additionally, Celera will receive milestone payments on reaching certain preclinical milestones. Celera retains certain diagnostic rights associated with selected targets.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.